WA
The startup develops anti-tumor therapeutics that target the tumor microenvironment (TME) to enhance the efficacy of existing antibody treatments for solid tumors. By addressing the limitations of current anticancer drugs, the company aims to improve treatment outcomes for cancer patients.
Updated 2 months ago
Funding
$750K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops anti-tumor therapeutics that target the tumor microenvironment (TME) to enhance the efficacy of existing antibody treatments for solid tumors. By addressing the limitations of current anticancer drugs, the company aims to improve treatment outcomes for cancer patients.